FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2003134638> ?p ?o ?g. }

• W2003134638 endingPage "1127" @default.
• W2003134638 startingPage "1121" @default.
• W2003134638 abstract "Purpose:The primary objective of this study was to determine the rate of pathological response after preoperative celecoxib and concurrent taxane-based chemotherapy in patients with cancer of the esophagus and gastroesophageal junction.Methods:Thirty-nine patients were enrolled in this single-arm, phase II clinical trial. Patients were administered daily celecoxib in combination with two to three cycles of carboplatin and paclitaxel with preoperative intent. Levels of cyclooxygenase (COX)-2 expression in resected tumors were analyzed by immunohistochemistry and correlated with clinical outcome measures. Postoperatively, patients were administered daily celecoxib for 1 year or until documented tumor recurrence.Results:All patients received two to three cycles of chemotherapy plus celecoxib 800 mg/d. Toxicities were as expected. A major clinical response (complete response + partial response) was noted in 22 patients (56%); six patients (15%) had a complete clinical response. Thirty-seven patients underwent esophagectomy. Five patients had a major pathological response (12.8%). Four-year overall and disease-free survivals were 40.9% and 30.3%, respectively. Patients with tumors expressing COX-2 demonstrated a higher likelihood of a major clinical response response (62% versus 50%) and an improved overall survival, compared with patients with COX-2-negative tumors.Conclusions:Preoperative celecoxib with concurrent chemotherapy demonstrated sufficient effect on pathologic response to warrant further study. Patients with tumors expressing COX-2 demonstrated trends toward improved response to preoperative therapy and improved overall survival compared with nonexpressors. The primary objective of this study was to determine the rate of pathological response after preoperative celecoxib and concurrent taxane-based chemotherapy in patients with cancer of the esophagus and gastroesophageal junction. Thirty-nine patients were enrolled in this single-arm, phase II clinical trial. Patients were administered daily celecoxib in combination with two to three cycles of carboplatin and paclitaxel with preoperative intent. Levels of cyclooxygenase (COX)-2 expression in resected tumors were analyzed by immunohistochemistry and correlated with clinical outcome measures. Postoperatively, patients were administered daily celecoxib for 1 year or until documented tumor recurrence. All patients received two to three cycles of chemotherapy plus celecoxib 800 mg/d. Toxicities were as expected. A major clinical response (complete response + partial response) was noted in 22 patients (56%); six patients (15%) had a complete clinical response. Thirty-seven patients underwent esophagectomy. Five patients had a major pathological response (12.8%). Four-year overall and disease-free survivals were 40.9% and 30.3%, respectively. Patients with tumors expressing COX-2 demonstrated a higher likelihood of a major clinical response response (62% versus 50%) and an improved overall survival, compared with patients with COX-2-negative tumors. Preoperative celecoxib with concurrent chemotherapy demonstrated sufficient effect on pathologic response to warrant further study. Patients with tumors expressing COX-2 demonstrated trends toward improved response to preoperative therapy and improved overall survival compared with nonexpressors." @default.
• W2003134638 created "2016-06-24" @default.
• W2003134638 creator A5005694878 @default.
• W2003134638 creator A5005774249 @default.
• W2003134638 creator A5018759987 @default.
• W2003134638 creator A5019783997 @default.
• W2003134638 creator A5020014751 @default.
• W2003134638 creator A5024592292 @default.
• W2003134638 creator A5033824271 @default.
• W2003134638 creator A5043186678 @default.
• W2003134638 creator A5052889912 @default.
• W2003134638 creator A5058195005 @default.
• W2003134638 creator A5059375706 @default.
• W2003134638 creator A5086908393 @default.
• W2003134638 date "2011-06-01" @default.
• W2003134638 modified "2023-09-30" @default.
• W2003134638 title "Preoperative Taxane-Based Chemotherapy and Celecoxib for Carcinoma of the Esophagus and Gastroesophageal Junction: Results of a Phase 2 Trial" @default.
• W2003134638 cites W1901180305 @default.
• W2003134638 cites W1966178564 @default.
• W2003134638 cites W1966473790 @default.
• W2003134638 cites W1990544952 @default.
• W2003134638 cites W2004924629 @default.
• W2003134638 cites W2008778808 @default.
• W2003134638 cites W2009406450 @default.
• W2003134638 cites W2012320279 @default.
• W2003134638 cites W2012901780 @default.
• W2003134638 cites W2028271271 @default.
• W2003134638 cites W2029409133 @default.
• W2003134638 cites W2032615620 @default.
• W2003134638 cites W2041676299 @default.
• W2003134638 cites W2051686420 @default.
• W2003134638 cites W2052409552 @default.
• W2003134638 cites W2062800226 @default.
• W2003134638 cites W2068219429 @default.
• W2003134638 cites W2075362684 @default.
• W2003134638 cites W2078922181 @default.
• W2003134638 cites W2100488521 @default.
• W2003134638 cites W2100974171 @default.
• W2003134638 cites W2100980775 @default.
• W2003134638 cites W2117011972 @default.
• W2003134638 cites W2120850551 @default.
• W2003134638 cites W2122352172 @default.
• W2003134638 cites W2123099168 @default.
• W2003134638 cites W2129746660 @default.
• W2003134638 cites W2132545630 @default.
• W2003134638 cites W2140615970 @default.
• W2003134638 cites W2153360030 @default.
• W2003134638 cites W2158968701 @default.
• W2003134638 cites W2159733409 @default.
• W2003134638 cites W2165429160 @default.
• W2003134638 cites W2204058214 @default.
• W2003134638 cites W2313229551 @default.
• W2003134638 cites W2336169581 @default.
• W2003134638 cites W2338880854 @default.
• W2003134638 cites W4300955892 @default.
• W2003134638 doi "https://doi.org/10.1097/jto.0b013e31821529a9" @default.
• W2003134638 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7457227" @default.
• W2003134638 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21532508" @default.
• W2003134638 hasPublicationYear "2011" @default.
• W2003134638 type Work @default.
• W2003134638 sameAs 2003134638 @default.
• W2003134638 citedByCount "21" @default.
• W2003134638 countsByYear W20031346382012 @default.
• W2003134638 countsByYear W20031346382013 @default.
• W2003134638 countsByYear W20031346382014 @default.
• W2003134638 countsByYear W20031346382015 @default.
• W2003134638 countsByYear W20031346382016 @default.
• W2003134638 countsByYear W20031346382017 @default.
• W2003134638 countsByYear W20031346382021 @default.
• W2003134638 countsByYear W20031346382022 @default.
• W2003134638 crossrefType "journal-article" @default.
• W2003134638 hasAuthorship W2003134638A5005694878 @default.
• W2003134638 hasAuthorship W2003134638A5005774249 @default.
• W2003134638 hasAuthorship W2003134638A5018759987 @default.
• W2003134638 hasAuthorship W2003134638A5019783997 @default.
• W2003134638 hasAuthorship W2003134638A5020014751 @default.
• W2003134638 hasAuthorship W2003134638A5024592292 @default.
• W2003134638 hasAuthorship W2003134638A5033824271 @default.
• W2003134638 hasAuthorship W2003134638A5043186678 @default.
• W2003134638 hasAuthorship W2003134638A5052889912 @default.
• W2003134638 hasAuthorship W2003134638A5058195005 @default.
• W2003134638 hasAuthorship W2003134638A5059375706 @default.
• W2003134638 hasAuthorship W2003134638A5086908393 @default.
• W2003134638 hasBestOaLocation W20031346381 @default.
• W2003134638 hasConcept C121608353 @default.
• W2003134638 hasConcept C126322002 @default.
• W2003134638 hasConcept C141071460 @default.
• W2003134638 hasConcept C143998085 @default.
• W2003134638 hasConcept C207886595 @default.
• W2003134638 hasConcept C2776467144 @default.
• W2003134638 hasConcept C2776694085 @default.
• W2003134638 hasConcept C2777297899 @default.
• W2003134638 hasConcept C2777511904 @default.
• W2003134638 hasConcept C2777546739 @default.
• W2003134638 hasConcept C2777819096 @default.
• W2003134638 hasConcept C2778239845 @default.
• W2003134638 hasConcept C2779742542 @default.
• W2003134638 hasConcept C2781451048 @default.

• next